Safeguard Scientifics Inc SFE
We take great care to ensure that the data presented and summarized in this overview for SAFEGUARD SCIENTIFICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SFE
View all-
North Run Capital, LP Wellesley, MA278KShares$219,4052.0% of portfolio
-
Zeke Capital Advisors, LLC Berwyn, PA250KShares$197,5000.05% of portfolio
-
Kistler Tiffany Companies, LLC Berwyn, PA364Shares$2870.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$00.0% of portfolio
Latest Institutional Activity in SFE
Top Purchases
Top Sells
About SFE
Safeguard Scientifics, Inc. no longer investing. It is a private equity and venture capital firm specializing in expansion financings, growth capital, management buyouts, recapitalizations, industry consolidations, corporate spinouts, growth stage, and early stage financings. It initially invests in a Series A-C round and opportunistically in a seed round. The firm prefers to make investments in companies engaged in the technology, financial services, and healthcare sector. Within the technology sector, it invests in software as a service, adtech / digital media, Internet of Everything, enhanced security, predictive analytics, machine learning, artificial intelligence, enterprise software, technology enabled services, internet/new media, financial technology, cloud, mobile, social, big data, in memory, and selected business services with capital requirements of up to $25 million. Within healthcare sector, the firm invests in molecular and point-of-care diagnostics, medical devices, regenerative medicine, medical technology, digital health, healthcare technology, specialty pharmaceuticals, and selected healthcare services. It invests throughout the United States with a focus on Mid-Atlantic region, and Southeastern Canada. The firm primarily invests between $5 million and $25 million in growth equity financing and between $5 million and $10 million in early-stage financing. It typically invests in the capital structures including owner financed and bootstrapped companies, corporate division or business unit, and venture capital-backed seeking a growth partner. The firm prefers to be the largest shareholder in its portfolio companies, with ownership in the range of 20 percent to 50 percent. However, it may occasionally take a majority or smaller stake in its portfolio companies. It prefers to invest in companies having proprietary technology and intellectual property. The firm prefers to take a Board seat in its portfolio companies. The company was founded in 1953 as Lancaster Corporation and changed its name to Safeguard Scientifics, Inc. in 1981. Safeguard Scientifics, Inc. is based in Radnor, Pennsylvania with additional office in Weston, Massachusetts.
Insider Transactions at SFE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 30
2024
|
Joseph M. Manko Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,087
+14.08%
|
$0
$0.71 P/Share
|
Jan 30
2024
|
Ross D De Mont Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,775
+6.74%
|
$0
$0.71 P/Share
|
Jan 30
2024
|
Beth Michelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,506
+15.12%
|
$0
$0.71 P/Share
|
Jan 30
2024
|
Russell D Glass Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,775
+10.03%
|
$0
$0.71 P/Share
|
Dec 15
2023
|
Eric Salzman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
68,858
-8.4%
|
$68,858
$1.03 P/Share
|
Dec 15
2023
|
Eric Salzman Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+23.12%
|
-
|
Nov 15
2023
|
Eric Salzman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,318
-1.8%
|
$5,318
$1.0 P/Share
|
Oct 16
2023
|
Joseph M. Manko Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
26,266
+11.91%
|
$26,266
$1.11 P/Share
|
Oct 16
2023
|
Eric Salzman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,298
-1.76%
|
$5,298
$1.11 P/Share
|
Oct 16
2023
|
Ross D De Mont Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,327
+5.1%
|
$14,327
$1.11 P/Share
|
Oct 16
2023
|
Beth Michelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,521
+13.0%
|
$15,521
$1.11 P/Share
|
Oct 16
2023
|
Russell D Glass Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,327
+7.96%
|
$14,327
$1.11 P/Share
|
Sep 15
2023
|
Eric Salzman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,298
-1.73%
|
$5,298
$1.13 P/Share
|
Aug 18
2023
|
Thomas A Satterfield Jr > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,899
-5.98%
|
$22,899
$1.17 P/Share
|
Aug 18
2023
|
Thomas A Satterfield Jr > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
50,000
+8.7%
|
$50,000
$1.17 P/Share
|
Aug 17
2023
|
Thomas A Satterfield Jr > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
241,196
-27.84%
|
$241,196
$1.18 P/Share
|
Aug 17
2023
|
Thomas A Satterfield Jr > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
15,000
+37.5%
|
$15,000
$1.19 P/Share
|
Aug 17
2023
|
Thomas A Satterfield Jr > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
229,000
+32.53%
|
$229,000
$1.18 P/Share
|
Aug 15
2023
|
Eric Salzman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,297
-1.7%
|
$5,297
$1.23 P/Share
|
Jul 17
2023
|
Joseph M. Manko Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,247
+9.31%
|
$17,247
$1.44 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 102K shares |
---|